The FAS gene, brain volume, and disease progression in Alzheimer's disease

Deniz Erten-Lyons, Anne Jacobson, Patricia Kramer, Andrew Grupe, Jeffrey Kaye

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Objective: We sought to identify single-nucleotide polymorphisms (SNPs) associated with Alzheimer's disease (AD) progression and brain volume. Methods: Ninety-seven SNPs were genotyped in 243 subjects from a longitudinal study of healthy aging. Subjects who received a diagnosis of cognitive impairment (CI) at any study visit (before their most recent visit) and had DNA in the study's DNA bank were included. Progression of AD was defined as the duration from onset of CI to diagnosis of AD. Association of each of the 97 SNPs with AD progression was tested via Cox model. Those SNPs meeting a criterion of nominal significance (P <0.05) for association with AD progression were reassessed to account for multiple testing by repeating the marker selection process in 10,000 random permutations. Next, the association between the one SNP that survived the multiple-testing adjustment and brain volume was determined by multiple regression analysis in a subgroup of subjects for whom magnetic-resonance imaging (MRI)-derived brain-volume data were available. Brain volumes were adjusted for age at MRI, gender, and time from MRI to onset of CI. Results: The minor allele of rs1468063 in the FAS gene, which is member 6 of the tumor necrosis factor receptor superfamily, was significantly associated with faster AD progression after adjustment for multiple testing (Ppermutation = 0.049). The same allele in rs1468063 was associated with smaller brain volumes and larger ventricular volumes (P = 0.02 and 0.04, respectively). Conclusions: The FAS gene, which plays a role in apoptosis, may be associated with AD by modulating the apoptosis and neuronal loss secondary to AD neuropathology.

Original languageEnglish (US)
Pages (from-to)118-124
Number of pages7
JournalAlzheimer's and Dementia
Volume6
Issue number2
DOIs
StatePublished - Mar 2010

Fingerprint

Brain Diseases
Disease Progression
Alzheimer Disease
Single Nucleotide Polymorphism
Genes
Brain
Magnetic Resonance Imaging
Alleles
Apoptosis
CD95 Antigens
Social Adjustment
DNA
Proportional Hazards Models
Longitudinal Studies
Regression Analysis
Cognitive Dysfunction

Keywords

  • Alzheimer's disease
  • Brain volume
  • FAS
  • Genetics
  • MRI

ASJC Scopus subject areas

  • Health Policy
  • Epidemiology
  • Geriatrics and Gerontology
  • Psychiatry and Mental health
  • Cellular and Molecular Neuroscience
  • Developmental Neuroscience
  • Clinical Neurology

Cite this

The FAS gene, brain volume, and disease progression in Alzheimer's disease. / Erten-Lyons, Deniz; Jacobson, Anne; Kramer, Patricia; Grupe, Andrew; Kaye, Jeffrey.

In: Alzheimer's and Dementia, Vol. 6, No. 2, 03.2010, p. 118-124.

Research output: Contribution to journalArticle

Erten-Lyons, Deniz ; Jacobson, Anne ; Kramer, Patricia ; Grupe, Andrew ; Kaye, Jeffrey. / The FAS gene, brain volume, and disease progression in Alzheimer's disease. In: Alzheimer's and Dementia. 2010 ; Vol. 6, No. 2. pp. 118-124.
@article{c4439e38283e4763a9e7064335b5e74a,
title = "The FAS gene, brain volume, and disease progression in Alzheimer's disease",
abstract = "Objective: We sought to identify single-nucleotide polymorphisms (SNPs) associated with Alzheimer's disease (AD) progression and brain volume. Methods: Ninety-seven SNPs were genotyped in 243 subjects from a longitudinal study of healthy aging. Subjects who received a diagnosis of cognitive impairment (CI) at any study visit (before their most recent visit) and had DNA in the study's DNA bank were included. Progression of AD was defined as the duration from onset of CI to diagnosis of AD. Association of each of the 97 SNPs with AD progression was tested via Cox model. Those SNPs meeting a criterion of nominal significance (P <0.05) for association with AD progression were reassessed to account for multiple testing by repeating the marker selection process in 10,000 random permutations. Next, the association between the one SNP that survived the multiple-testing adjustment and brain volume was determined by multiple regression analysis in a subgroup of subjects for whom magnetic-resonance imaging (MRI)-derived brain-volume data were available. Brain volumes were adjusted for age at MRI, gender, and time from MRI to onset of CI. Results: The minor allele of rs1468063 in the FAS gene, which is member 6 of the tumor necrosis factor receptor superfamily, was significantly associated with faster AD progression after adjustment for multiple testing (Ppermutation = 0.049). The same allele in rs1468063 was associated with smaller brain volumes and larger ventricular volumes (P = 0.02 and 0.04, respectively). Conclusions: The FAS gene, which plays a role in apoptosis, may be associated with AD by modulating the apoptosis and neuronal loss secondary to AD neuropathology.",
keywords = "Alzheimer's disease, Brain volume, FAS, Genetics, MRI",
author = "Deniz Erten-Lyons and Anne Jacobson and Patricia Kramer and Andrew Grupe and Jeffrey Kaye",
year = "2010",
month = "3",
doi = "10.1016/j.jalz.2009.05.663",
language = "English (US)",
volume = "6",
pages = "118--124",
journal = "Alzheimer's and Dementia",
issn = "1552-5260",
publisher = "Elsevier Inc.",
number = "2",

}

TY - JOUR

T1 - The FAS gene, brain volume, and disease progression in Alzheimer's disease

AU - Erten-Lyons, Deniz

AU - Jacobson, Anne

AU - Kramer, Patricia

AU - Grupe, Andrew

AU - Kaye, Jeffrey

PY - 2010/3

Y1 - 2010/3

N2 - Objective: We sought to identify single-nucleotide polymorphisms (SNPs) associated with Alzheimer's disease (AD) progression and brain volume. Methods: Ninety-seven SNPs were genotyped in 243 subjects from a longitudinal study of healthy aging. Subjects who received a diagnosis of cognitive impairment (CI) at any study visit (before their most recent visit) and had DNA in the study's DNA bank were included. Progression of AD was defined as the duration from onset of CI to diagnosis of AD. Association of each of the 97 SNPs with AD progression was tested via Cox model. Those SNPs meeting a criterion of nominal significance (P <0.05) for association with AD progression were reassessed to account for multiple testing by repeating the marker selection process in 10,000 random permutations. Next, the association between the one SNP that survived the multiple-testing adjustment and brain volume was determined by multiple regression analysis in a subgroup of subjects for whom magnetic-resonance imaging (MRI)-derived brain-volume data were available. Brain volumes were adjusted for age at MRI, gender, and time from MRI to onset of CI. Results: The minor allele of rs1468063 in the FAS gene, which is member 6 of the tumor necrosis factor receptor superfamily, was significantly associated with faster AD progression after adjustment for multiple testing (Ppermutation = 0.049). The same allele in rs1468063 was associated with smaller brain volumes and larger ventricular volumes (P = 0.02 and 0.04, respectively). Conclusions: The FAS gene, which plays a role in apoptosis, may be associated with AD by modulating the apoptosis and neuronal loss secondary to AD neuropathology.

AB - Objective: We sought to identify single-nucleotide polymorphisms (SNPs) associated with Alzheimer's disease (AD) progression and brain volume. Methods: Ninety-seven SNPs were genotyped in 243 subjects from a longitudinal study of healthy aging. Subjects who received a diagnosis of cognitive impairment (CI) at any study visit (before their most recent visit) and had DNA in the study's DNA bank were included. Progression of AD was defined as the duration from onset of CI to diagnosis of AD. Association of each of the 97 SNPs with AD progression was tested via Cox model. Those SNPs meeting a criterion of nominal significance (P <0.05) for association with AD progression were reassessed to account for multiple testing by repeating the marker selection process in 10,000 random permutations. Next, the association between the one SNP that survived the multiple-testing adjustment and brain volume was determined by multiple regression analysis in a subgroup of subjects for whom magnetic-resonance imaging (MRI)-derived brain-volume data were available. Brain volumes were adjusted for age at MRI, gender, and time from MRI to onset of CI. Results: The minor allele of rs1468063 in the FAS gene, which is member 6 of the tumor necrosis factor receptor superfamily, was significantly associated with faster AD progression after adjustment for multiple testing (Ppermutation = 0.049). The same allele in rs1468063 was associated with smaller brain volumes and larger ventricular volumes (P = 0.02 and 0.04, respectively). Conclusions: The FAS gene, which plays a role in apoptosis, may be associated with AD by modulating the apoptosis and neuronal loss secondary to AD neuropathology.

KW - Alzheimer's disease

KW - Brain volume

KW - FAS

KW - Genetics

KW - MRI

UR - http://www.scopus.com/inward/record.url?scp=77949338415&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77949338415&partnerID=8YFLogxK

U2 - 10.1016/j.jalz.2009.05.663

DO - 10.1016/j.jalz.2009.05.663

M3 - Article

C2 - 19766542

AN - SCOPUS:77949338415

VL - 6

SP - 118

EP - 124

JO - Alzheimer's and Dementia

JF - Alzheimer's and Dementia

SN - 1552-5260

IS - 2

ER -